|
PCNX expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.07719999999467E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.90459999999915E-05 |
| Normal-vs-Stage2 |
4.395200E-01 |
| Normal-vs-Stage3 |
1.00229999999701E-06 |
| Normal-vs-Stage4 |
2.7855999951143E-08 |
| Stage1-vs-Stage2 |
4.647500E-02 |
| Stage1-vs-Stage3 |
5.550200E-02 |
| Stage1-vs-Stage4 |
3.716200E-03 |
| Stage2-vs-Stage3 |
4.283200E-03 |
| Stage2-vs-Stage4 |
2.773200E-04 |
| Stage3-vs-Stage4 |
1.795570E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.1454999999988E-07 |
| Normal-vs-AfricanAmerican |
1.558370E-02 |
| Normal-vs-Asian |
4.12370000000273E-05 |
| Caucasian-vs-AfricanAmerican |
5.654000E-01 |
| Caucasian-vs-Asian |
6.708600E-01 |
| AfricanAmerican-vs-Asian |
4.216200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.74170000003071E-06 |
| Normal-vs-Female |
1.204390E-04 |
| Male-vs-Female |
1.107800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.370740E-04 |
| Normal-vs-Age(41-60Yrs) |
1.998310E-04 |
| Normal-vs-Age(61-80Yrs) |
4.19390000000464E-05 |
| Normal-vs-Age(81-100Yrs) |
1.373830E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.823600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.512600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.812800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.237000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.216400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.559200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.263500E-02 |
| Classical-VS-Follicular |
1.055450E-01 |
| Classical-VS-Other |
9.018100E-02 |
| Classical-VS-Normal |
1.68656999999239E-05 |
| Tall-VS-Follicular |
2.460500E-03 |
| Tall-VS-Other |
6.016000E-01 |
| Tall-VS-Normal |
3.1503999999849E-06 |
| Follicular-VS-Other |
9.252400E-02 |
| Follicular-VS-Normal |
5.625700E-02 |
| Other-VS-Normal |
1.980750E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.401000E-04 |
| Normal-vs-N1 |
8.18309999761624E-08 |
| N0-vs-N1 |
5.959400E-03 |
|
|
